Long term subjective cure rate, urinary tract symptoms and dyspareunia following mesh augmented anterior vaginal wall prolapse repair

• We interviewed 79 women 79–104 months after anterior pelvic floor repair with mesh.
• 11 (13.9%) reported recurrence of prolapse, mostly in the posterior compartment.
• 6 needed a corrective procedure and one had her mesh removed due to dyspareunia.
• 11 (13.9%) reported lower urinary tract symptoms other than prolapse.
• Overall, long term patient centered outcomes were positive.

IntroductionThe aim of this study was to assess patient-centered long term outcomes following anterior vaginal repair with mesh.MethodsIn January 2015, we identified 124 women who underwent anterior pelvic floor repair with mesh between January 2006 and February 2009. Patient records were reviewed and demographic, clinical, intra-operative and post-operative follow-up data retrieved. Telephone interviews were conducted to access information on clinical outcomes. Associations between baseline characteristics and long term symptoms were assessed by multivariable logistic regression models.ResultsSeventy-nine women were reached and consented to participate. Patients were interviewed 79–104 months after surgery. Their mean age at the time of surgery was 62.48 ± 9.53 years; all had stage III cystocele with a mean POP Q point Ba of 5.32 ± 1.47. Twenty-four (30%) had a previous hysterectomy and 26 (33%) had a previous pelvic organ prolapse or stress urinary incontinence operation. At telephone interviews, recurrence of prolapse symptoms was reported by 11 (13.9%) patients, mostly in the posterior compartment. Only 6 needed a corrective procedure. One patient had her mesh removed due to dyspareunia. Eleven (13.9%) reported lower urinary tract symptoms other than prolapse, as follows: stress urinary incontinence (1), overactive bladder (8) and dyspareunia (2).ConclusionLong term rates of recurrent prolapse, dyspareunia and lower urinary tract symptoms were low for patients who underwent anterior vaginal wall mesh augmentation surgery for symptomatic cystoceles.